The pattern of circulating iodothyronines in the fetus differs from that in the adult, being characterized by low levels of serum T 3 . In this study, concentrations of various iodothyronines were measured in sera from neonates of various postconceptional age (PA). Results obtained in cord sera at birth (PA, (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40), reflecting the fetal pattern, were compared with those found during extrauterine life in newborns of 5 days or more of postnatal life (PA, 27-46 weeks). The main findings are: Starting at 30 weeks of PA, serum levels increase linearly during extrauterine life; and at 40 weeks, they are more than 200% of those measured in cord sera from newborns of equivalent PA. Serum reverse T 3 (rT3) levels during fetal life are higher than those measured during extrauterine life; but they significantly decrease, starting at 30 weeks of PA. Serum T 3 sulfate (T3S) does not significantly differ between the two groups, showing the highest values at 28 -30 weeks of PA, and significantly decreasing at 30 -40 weeks. T3S levels are directly correlated with rT3, both in fetal and extrauterine life, whereas a significant negative correlation between T3S and T 3 is found only during extrauterine life. In conclusion: 1) changes in serum concentrations of iodothyronines in umbilical cord and during postnatal life indicate that maturation of extrathyroidal type I-iodothyronine monodeiodinase (MD) accelerates, starting at 30 weeks of PA; 2) high levels of type III-MD activity in fetal tissues prevent the rise of serum T 3 , whereas they maintain high levels of rT3 during intrauterine life; 3) an important mechanism leading to the transition from the fetal to the postnatal thyroid hormone balance is a sudden decrease in type III-MD activity; iv) because placenta contains a high amount of type III-MD, it is conceivable that placenta contributes to maintain low T 3 and high rT3 serum concentrations during fetal life and that its removal at birth is responsible for most changes in iodothyronine metabolism occurring afterwards. (J Clin Endocrinol Metab 84: [493][494][495][496][497][498] 1999) T HE PATTERN of circulating iodothyronines in the fetus differs from that in the adult, being characterized by low levels of serum T 3 . To support optimal growth and differentiation, sufficient amounts of T 3 can be provided to selected tissues by local deiodination of T 4 (1, 2). The low T 3 state in the fetus is attributed to a different balance, as compared with the adult, among different iodothyronine monodeiodinases (MDs) (3). The relationship between serum iodothyronines and iodothyronine MDs has been investigated in several species (4), and low levels of type I-iodothyronine MD (type I-MD), which generates T 3 from T 4 , have been found in extrathyroidal fetal tissues (5-8). Serum levels of reverse T 3 (rT3) (which is produced by 5-monodeiodination of T 4 ) and those of T 3 sulfate (T3S) (which is produced by enzymatic sulfation of T 3 ) are elevated in the fetus (9, 10). Because both rT3 and T3S are quickly deiodinated by type I-MD, it is commonly believed that a low metabolic clearance rate of these iodothyronines is responsible for their high serum concentrations in the fetus. However, it is unclear whether the low type I-MD activity by itself may account for all the differences in serum levels of iodothyronines observed in the fetus, as compared with the adult. Indeed, fetal tissues exhibit high levels of type III-iodothyronine MD (type III-MD) activity, which generates rT3 from T 4 and degrades T 3 to 3,3Ј-diiodothyronine (T 2 ) (11, 12). It is supposed that this enzyme activity contributes to maintain the low T 3 state during intrauterine life (3, 13).
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In the present study, serum levels of different iodothyronines were evaluated in human newborns of various gestational stages. Iodothyronines were measured at birth and thereafter at several time points, up to 3 months of postnatal age. The relationship among various iodothyronines and the changes occurring after delivery were evaluated based on the postconceptional age (PA).
Subjects and Methods Newborns
The population studied was a hospital-based cohort of neonates born at the Pisa Neonatal Unit, S. Chiara Hospital, Pisa, Italy. We studied 118 full-term newborns born at 36 -40 weeks of PA. The mean PA Ϯ sd was 37.7 Ϯ 1 week, with a mean birth weight Ϯ sd of 3.4 Ϯ 0.4 kg. In addition, we studied 156 preterm newborns at 24 -35 weeks of PA. The mean PA of this group Ϯ sd was 29.9 Ϯ 2.9 weeks, with a mean birth weight Ϯ sd of 1.6 Ϯ 0.7 kg. PA was calculated based on the first day of the last menstrual period (minus 2 weeks) and from early ultrasonographic examinations. PA was verified by clinical assessment of the infant, at birth, using the method of Dubowitz and Dubowitz (14) . All infants were without malformations, infections, or major clinical problems, except respiratory distress syndrome in preterm newborns. The mothers of preterm neonates did not receive steroid treatment before delivery. Informed parental consent was obtained.
Collection of blood samples and laboratory methods
Blood was drawn from the umbilical cords of 69 newborns immediately after ligation. Venous blood was obtained from 205 infants between 6 h and 14 weeks of postnatal life. Infants taking drugs known to affect thyroid hormone secretion or metabolism were excluded.
Serum T3S levels were measured by RIA, as described previously (15) . The range of T3S values in normal adults is 13-79 pmol/L. Total T 3 (TT3) and total T 4 (TT4) were measured using indirect methods (Method Spac Byk-Sangtec Diagnostic, Dietzenbach, Germany). rT3 and 
Statistical analysis
Regression analysis was used to evaluate the relationship between different iodothyronines and between iodothyronine concentrations and PA. Student's t test for unpaired data was used to compare means of serum iodothyronines in different groups.
Results

Serum levels of iodothyronines in preterm and full-term newborns
Mean levels of T3S in umbilical cord serum of 69 newborns of various PA are shown in Fig. 1 . Results of serum T3S from 205 infants between 6 h and 14 weeks of postnatal life are also shown there. High serum levels of T3S begin to decrease at about 30 weeks of PA. Soon after delivery, there is a sharp increase in serum T3S, which peaks at day 2 of extrauterine life. The concentrations then decline quickly, up to day 5, when mean T3S values are similar to those in umbilical cord at the time of delivery. Thereafter, serum T3S levels slowly decrease, and in full-term neonates, they reach the adult range at about 14 weeks of extrauterine life. The postnatal T3S peak (day 1-4) is higher in preterm newborns, as compared with full-term newborns (P Ͻ 0.001). The mean serum concentrations of T3S, at various times after birth, were always higher in preterm (as compared with full-term) newborns of equivalent postnatal age (Fig. 1) . From the 3rd week of postnatal life onward, the mean serum levels of T3S were significantly lower than during fetal life, both in preterm (P Ͻ 0.001) and full-term infants (P Ͻ 0.001). Figure 2 shows the mean TT3, TT4, and rT3 concentrations during fetal life (as assessed in cord sera at birth) and during early extrauterine life (as assessed in full-term newborns). Data in Fig. 2 are in keeping with those previously reported in the literature, although the increase in serum T 3 in the fetus after 30 weeks of gestation was more marked in earlier studies (16, 17) .
T3S values in cord sera from newborns of various PA show a significant direct correlation with rT3 values (r ϭ 0.56, P Ͻ 0.001) (Fig. 3A) but not with TT3, TT4, FT3, FT4, or TBG concentrations (data not shown). In neonates 5 days or more postnatal age (i.e. after the peaks of T 3 , T 4 and T3S), serum T3S concentrations are directly correlated with rT3 concentrations (r ϭ 0.39, P Ͻ 0.001, Fig. 3B ). At the same postnatal age, an inverse correlation is observed between T3S and TT3 (r ϭ 0.39, P Ͻ 0.001) or FT3 (r ϭ 0.41, P Ͻ 0.001) (Fig. 4) , whereas no correlation is observed between T3S and TT4, FT4, or TBG (data not shown).
Comparison between fetal and neonatal concentrations of serum iodothyronines
To understand the mechanisms that regulate serum iodothyronine concentrations in utero vs. postnatal life, we compared the results obtained in cord sera at birth (group A), reflecting the fetal condition, with those found in newborns of 5 days or more postnatal age, within the same range of PA (group B). Figure 5 shows the relationship between PA and serum levels of TT3 in the two groups. Serum concentrations Serum levels of rT3 significantly decrease in the last weeks of fetal life, as shown by an inverse correlation between rT3 and PA (r ϭ 0.51, P Ͻ 0.001) in group A (Fig. 6A) . Serum rT3 in the neonate (Ն5 days old, group B) is much lower than in the fetus (group A) and does not show major changes with PA (Fig. 6B) . With increasing PA, a decrease in serum T3S (Fig. 7) and an increase in serum TT4 (Fig. 8 ) levels occur, both in the fetus and in the neonate. The mean serum concentrations of TT3, rT3, T3S, and TT4 in full-term fetuses and in neonates of corresponding PA are shown in Table 1 . Although there is no difference in T3S and TT4 serum concentrations, TT3 is greater than 200%, and rT3 is lower than 55%, in neonates (as compared with fetuses).
Discussion
The iodothyronine status in the fetus differs from that in the adult, being characterized by low serum T 3 associated with high levels of rT3 and sulfated iodothyronines (3, 15, 18 -20) . T3S can be detected in human fetal serum as early as 19 weeks of gestation, and its concentration increases with the progression of pregnancy (10) . In this study, we observed that serum T3S reaches its highest concentration during the eighth month of gestation. At that time, T3S levels are nearly 10 times higher than in adult life. Thereafter, serum T3S begins to decrease; and in full-term newborns, it progressively reaches the adult range during the fourth postnatal month. Serum T3S levels reflect the activity of type I-MD, because this enzyme promptly degrades T3S to T2S (21, 22) . Thus, our data suggest that extrathyroidal type I-MD activity, which is low in the fetus throughout pregnancy, increases (starting at the eighth month of gestation) and that this process of maturation continues in the first few months after birth. In keeping with this concept, we found that serum levels of rT3, which also accumulates when type I-MD activity is low, are directly related to those of T3S. This is the case, both in umbilical cord serum (reflecting intrauterine thyroid hormone metabolism) and during early extrauterine life.
Our results also show that the progressive decline in serum levels of T3S, during late intrauterine and early extrauterine life, is briefly interrupted by a sharp peak on day 2 after birth. In our view, this transient rise in serum T3S concentration reflects the postnatal peak of T 3 (23) . T 3 is the substrate for sulfotransferase enzymes that produce T3S (24) . The concomitant serum rise of T 3 and T3S indicates that the postnatal surge of T 3 is mainly caused by an enhanced thyroidal secretion, rather than by an increased peripheral conversion of T 4 to T 3 by type I-MD. This is because an increased activity of peripheral type I-MD, though raising serum T 3 levels, would accelerate the metabolic clearance rate of T3S and ultimately decrease serum concentrations of T3S (25, 26) . In keeping with this view, once the postnatal peak of T 3 and T3S fades, there is an inverse relationship between serum levels of T3S and T 3 . These data support the concept that the maturation of peripheral type I-MD activity continues after birth and is responsible for the progressive decline in serum T3S levels. Surprisingly, we did not find an inverse relationship between T3S and T 3 levels in umbilical cord sera, because the decrease in serum T3S during the last weeks of gestation was not associated with a corresponding rise of T 3 . To explain why serum T 3 does not rise as expected, we analyzed the results obtained 5 or more days after birth in neonates with a PA ranging from 27-46 weeks. We considered results that were obtained at age 5 days or more, to avoid the interference caused by the postnatal peak of iodothyronines. At variance with results in cord sera, during extrauterine life, serum levels of T 3 begin to rise, as early as 30 weeks of PA, and reach the adult range approximately 3 months later. This T 3 profile fits with the concept that the maturation of peripheral type I-MD starts at 30 weeks of PA (16) . In keeping with this estimate, a previous study (27) showed that l-T 4 administration to very premature newborns (Ͻ30 weeks of gestational age) produces an increase in serum levels of T 4 and rT3 but not of T 3 , indicating that peripheral type I-MD activity is low at this stage of development. l-T 4 administration to full-term hypothyroid newborns normalizes serum T 3 , confirming that, at this stage, the ability of extrathyroidal tissues to produce T 3 has been achieved (28) .
Thus, if type I-MD matures, starting at 30 weeks of PA, why then, don't serum levels of T 3 increase as expected during intrauterine life? A reasonable explanation for these findings takes into account the role of the placenta. Though the placenta is rich in the type III-MD enzyme, which deiodinates T 4 to rT3, and T 3 to T 2 , it does not metabolize sulfated iodothyronines (10, 11, 29, 30) . Common belief says that the main role of placental type III-MD is to limit the transfer of maternal thyroid hormones to the fetus (31) . Our data suggest that placental type III-MD is important also in regulating the metabolism of iodothyronines originated in the fetus. The major role of this enzyme would consist of maintaining serum T 3 at a low level during intrauterine life, by supporting a high metabolic clearance rate of this hormone. This mechanism has a particular relevance in late gestation, because it prevents a rise in serum T 3 levels, while allowing a maturation of the peripheral machinery (type I-MD) responsible for the production of T 3 . Exclusion of the placenta from fetal circulation at birth allows a quick rise in serum T 3 levels, because the production rate of T 3 is no longer counterbalanced by the high degradation rate caused by placental type III-MD. This mechanism would account for the above reported observation that serum levels of T 3 are lower in fetuses than in neonates of the same PA. Beside T 3 -to-T 2 conversion, type III-MD also catalyzes the monodeiodination of T 4 to rT3. This can explain the finding that serum levels of rT3 are higher in fetuses than in neonates of the same PA. Because T3S is not deiodinated by type III-MD, the placenta does not influence the serum levels of this metabolite. As a consequence, serum levels of T3S are superimposable during fetal and extrauterine life, provided that PA is the same (see Table 1 ).
Previous data support our view that placental type III-MD activity plays an important role in regulating serum levels of T 3 and rT3 during intrauterine life. In human embryos, rT3 is much higher in celomic fluid than in amniotic fluid or maternal serum (32) , suggesting that the placenta is the most active site for the production of rT3. In newborn lambs, the thyroid gland is the major source of circulating T 3 during early hours after delivery, in response to the TSH postnatal surge (33) . However, the postnatal T 3 peak can be delayed well after the TSH peak, by delaying the umbilical cord cutting (34) . In our view, this implies that the interruption of T 3 degradation by placental type III-MD is important in allowing the postnatal T 3 surge. Most neonates developing neonatal hyperthyroidism caused by the transplacental passage of thyroid-stimulating antibody have normal T 3 levels at birth and become clinically thyrotoxic during the first week after delivery (35) . It is conceivable that placental type III-MD has a protective role towards the development of thyrotoxicosis, by degrading excess T 3 in utero.
The transition from the low T 3 state of fetal life to the thyroid hormone pattern of infancy is believed to involve two main mechanisms. The acute postnatal release of TSH produces an early peak in serum T 3 concentrations, as a result of enhanced thyroidal secretion (23, 36) . The subsequent maintenance of serum T 3 levels is attributed to an increased T 4 -to-T 3 conversion by peripheral deiodinases (3, 16) . Our findings suggest that an additional important mechanism consists of the abrupt reduction of T 3 degradation by placenta after umbilical cord cutting.
Other factors may intervene in the regulation of serum iodothyronines in the fetus. Both T 3 and rT3 share T 4 as their precursor, and their serum levels are influenced by thyroidal T 4 secretion, which progressively increases with PA. A high production rate of T3S by sulfotransferases may contribute to the maintenance of high serum T3S (37) . Fetal liver type III-MD may play a role in lowering serum T 3 (38) . Finally, type II-MD activity might be important in regulating serum T 3 levels (39).
In conclusion, our main findings are: 1) changes in serum concentrations of iodothyronines, during fetal life and in the postnatal period, confirm that maturation of extrathyroidal type I-iodothyronine MD accelerates, starting at 30 weeks of PA; 2) high levels of type III-MD activity in fetal tissues prevent the rise of serum T 3 , while maintaining high levels of rT3 during intrauterine life; 3) an important mechanism leading to the transition from fetal to postnatal thyroid hormone balance is a decrease of type III-MD activity; 4) because the placenta contains a high amount of type III-MD, it is conceivable that the placenta contributes to maintenance of low T 3 and high rT3 serum concentrations during fetal life and that its removal at birth is responsible for most changes in iodothyronine metabolism occurring afterwards.
